Interested in our pipeline and platform technologies?
Join me in Lisbon for three days of partnering at BIO Europe Spring.
We’re actively looking for investors and co‑development partners across our CNS portfolio:
– A first‑in‑class, BBB‑penetrant small molecule activating a novel intracellular α‑synuclein clearance mechanism
– A human microglia platform enabling patient‑based discovery for neuroinflammation
– A small‑molecule hit series for Phelan‑McDermid Syndrome, a genetically defined subgroup of Autism Spectrum Disorders
– A versatile discovery platform to accelerate next‑generation, patient‑based drug development programs.
